Dermatology’s growing focus on skin longevity demands clear definitions, validated outcomes, and rigorous evidence beyond anti-aging claims.
Blog|Articles|November 8, 2023
Pointers With Portela: Retinol Alternatives
Author(s)Dustin Portela, DO
In this week’s Pointers With Portela, the 208SkinDoc discusses the best retinol alternatives in 2023.
Advertisement
In his most recent YouTube episode, "Best Retinol Alternatives in 2023"
Some of Portela's retinol alternatives include:
- Bakuchiol
- Glycolic acid
- Azelaic acid
Opinions expressed are that of Portela and do not express the views or opinions of Dermatology Times®.
Dr Portela's social media channels:
YouTube:
2.
Instagram:
X (formerly known as Twitter):
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Benjamin Ungar, MD, moderated a recent Dermatology Times Case-Based Roundtable event on how to define severity, choose among JAK inhibitors, and monitor patients with alopecia areata.
Clinicians at a Dermatology Times Case-Based Roundtable, moderated by Chesahna Kindred, MD, debated when to escalate to oral JAK inhibitors for alopecia areata and how to counsel patients on timing, monitoring, and safety.
The joint AAD-HSF guideline issues 37 recommendations, including strong support for adalimumab, bimekizumab, infliximab, and secukinumab.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
2
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
3
Individualizing Systemic Therapy for Alopecia Areata Across Patient Cases
4
Skin Longevity Needs Evidence, Not Hype
5